Sling Therapeutics

Sling Therapeutics is a clinical-stage biopharmaceutical company focused on the late-stage advancement of an oral small molecule therapy for the treatment of thyroid eye disease (TED).

Linsitinib, an IGF-1R (insulin-like growth factor 1 receptor) inhibitor, is designed to provide TED patients with an effective, convenient oral treatment option while reducing the treatment burden on patients, physicians and the healthcare system. 

Its team, consisting of highly experienced executives, drug developers, and scientific advisors, works with urgency to develop additional therapies for patients while upholding the highest standards of quality.